Effectiveness of COVID-19 Vaccines Against SARS-CoV-2 Infection During a Delta Variant Epidemic Surge in Multnomah County, Oregon, July 2021

Russell S. Barlow¹, Kevin Jian¹, Lindsey Larson^{1,2}

¹*Multnomah County Health Department, Communicable Disease Services, Portland Oregon USA*

²*Council of State and Territorial Epidemiologists (CSTE), Applied Epidemiology Fellowship Program*

Corresponding Author:

Russell S. Barlow

Communicable Disease Services, Multnomah County Health Department

619 NW 6th Ave, 4th floor,

Portland, Oregon 97209.

Email: russell.barlow@multco.us

Abstract

Background: Coronavirus disease 2019 (COVID-19) vaccines have been shown to be highly effective in preventing SARS-CoV-2 infection within controlled trials and real-world vaccine effectiveness (VE) studies. Recent reports have estimated reduced VE with the emergence and dissemination of the B.1.617.2 variant (“Delta variant”). We assess VE in Multnomah County, Oregon during a delta variant related epidemic expansion.

Methods: A test-negative design (TND) matched case-control analysis was performed to estimate the effectiveness of vaccination against SARS-CoV-2 infection during July 2021. Cases included a random sample of individuals that tested positive for SARS-CoV-2 and were reported by electronic laboratory report, were >15 years of age, and had no prior known SARS-CoV-2 infections. Controls were age and postal code matched individuals that tested negative for SARS-CoV-2 during July 2021. Immunization status was assessed using the Oregon ALERT Immunization Information system.

Results: 500 case-control pairs were matched (n=1000). 40.4% of cases were up-to-date on COVID-19 immunizations compared to 64.6% of controls. Effectiveness of any completed COVID-19 immunization was 73% (95% Confidence Interval [CI] 49-86%), 74% (95% CI 65-85%) for mRNA immunizations (BNT162b2, mRNA-1273), and 72% (95% CI 47-85%) for individuals partially immunized with mRNA immunizations.

Conclusions: Our findings estimate high, yet reduced, VE during Delta variant dissemination. These results highlight the importance of COVID-19 immunizations for reducing SARS-CoV-2 infection while juxtaposing the need for additional non-pharmaceutical interventions. Importantly, the reduced VE identified here may predict future reductions in vaccine performance in the context of ongoing viral genetic drift.

Introduction

SARS-CoV-2 has infected over 210 million individuals worldwide resulting in 4.4 million deaths as of August 17, 2021 [1]. Immunizations targeting the SARS-CoV-2 spike protein have been developed to prevent Coronavirus disease 2019 (COVID-19). In the United States (US), three immunizations have been granted Food and Drug Administration Emergency Use Authorization (FDA EUA) with Advisory Council on Immunization Practices (ACIP) recommendations including: Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1273) mRNA vaccines, and Janssen's (Ad26.COV2.S) adenovirus vaccine [2-7]. Results from phase 3 randomized controlled trials of BNT162b2 and mRNA-1273 demonstrated high two-dose vaccine efficacy (~95%) for preventing SARS-CoV-2 infection and COVID-19 with subsequent high vaccine efficacy at 6 month interim analyses [8-10]. Clinical trial results from Ad26.COV2.S demonstrated moderate single-dose efficacy (66.3%) in preventing COVID-19 [11]. Similarly, high vaccine effectiveness (VE) has been reported across several national and international observational studies for the mRNA vaccines[12-20].

Recent reports have indicated elevated vaccine breakthrough infections in the context of reduced prophylactic VE against the SARS-CoV-2 B.1.617.2 variant ("Delta variant") with conflicting VE estimates ranging from 40%-88% [21-25]. Interpretation of these reports is complicated by differences in methods, study populations, care settings, immunization timelines, and possible selection and case ascertainment biases. To date, no studies have provided robust estimates of VE within a metropolitan population.

Multnomah County Health Department (MCHD) in Portland, Oregon monitors vaccine uptake and performance as part of our COVID-19 response. Previously, we evaluated baseline VE after immunization prevalence plateaued locally (65% of the total population immunized) in June, 2021 (unpublished supplemental data). Utilizing a test-negative design (TND) case-control approach, we estimated high VE consistent with published clinical trials and observational studies [12-20]. During July 2021, Multnomah County experienced a COVID-19 epidemic expansion likely driven by insufficient immunization coverage, increased social mixing, and the predominance of Delta variant (From 4% of sequenced cases during June to >75% during July 2021). This provided an opportunity to evaluate vaccine performance during Delta variant dissemination. Therefore, we performed a subsequent TND matched case-control assessment to provide instantaneous (point-in-time) countywide VE estimates during this epidemic expansion.

Methods

Assessment Population and Oregon's COVID-19 Surveillance System

MCHD conducts active laboratory based surveillance of COVID-19 for 829,000 residents, who account for 19% of Oregon's population [26]. Following ACIP guidance, Oregon began administering BNT162b2 and mRNA-1273 in December 2020 and subsequently Ad26.COV2.S in February 2021 to select populations [5-7]. Immunization eligibility was opened to all individuals >15 years of age during April 2021. By July 1st 2021, 70% of the county population over 15 years of age were estimated to have completed a COVID-19 immunization series with roughly 69% of those individuals receiving BNT162b2, 24% mRNA-1273, and 6% Ad26.COV2.S (unpublished data, [27]).

Physicians and laboratories are legally required to report all SARS-CoV-2 laboratory testing (positive, inconclusive, and negative) and clinically suspected cases of COVID-19 to local health departments via electronic laboratory reporting (ELR) or, in select settings, electronic case reporting (eCR), with demographic and clinical information. Data monitoring for consistency and completeness is performed

on a routine basis including data linkage to the Oregon ALERT Immunizations Information System (ALERT IIS).

SARS-CoV-2 Case and Control Definitions and Inclusion Criteria

To estimate COVID-19 vaccine performance against SARS-CoV-2 infection we utilized a TND matched case-control design including individuals that were tested for SARS-CoV-2 during July 2021 [28].

Cases: Primary SARS-CoV-2 infections among 15+ year olds that tested positive between July 1st and July 31st 2021 with an FDA EUA approved polymerase chain reaction (RT-PCR) or antigen test reported via ELR. Cases reported via eCR were not included for the following reasons: 1) eCR results are biased towards positive tests, 2) eCR testing primarily occurs within congregate settings and special populations where the prevalence of immunization, prevalence of testing, and prevalence of disease are often different from the general population (i.e. known or suspected effect modification).

Controls: ELR reported individuals >15 years of age that tested negative for SARS-CoV-2 with an FDA EUA approved RT-PCR or Antigen test between July 1st and July 31st 2021. If eligible controls were tested more than one time during the study period, they were only available for selection once.

Vaccination Status Determination

Providers administering COVID-19 immunizations in Oregon are required to input immunizations into ALERT IIS within 72hrs of administration. Vaccination history was obtained by manually querying ALERT IIS for dates, type, and manufacturer for both cases and controls. Only provider-documented doses of vaccine were included in our assessment of vaccination status.

Vaccination status was determined according to the ACIP recommendations for all FDA EUA COVID-19 immunizations. For BNT162b2, 2 doses are required to be administered at least 21 days apart; for mRNA-1273, 2 doses are required to be administered at least 28 days apart; for Ad26.COV2.S a single dose was required [5-7]. To minimize differential exposure biases, the specimen date for the case was used to assess immunization status for both the case and the matched control. Shots were considered invalid if they were administered <14 days prior to the case's positive test collection date.

Persons meeting the ACIP criteria for immunization were classified as up-to-date (abbreviated UTD). Persons who received prior valid COVID-19 immunizations (BNT162b2 and mRNA-1273 only) but failed to meet the ACIP criteria were classified as previously vaccinated, not up-to-date (abbreviated NUTD). Persons with no documented doses were classified as unvaccinated.

Statistical Analyses

Both cases and controls were excluded from selection if they had documented prior RT-PCR or antigen confirmed SARS-CoV-2 infections. From the eligible cases, 500 were selected using simple random sampling. Eligible controls were stratified by age and postal code and were randomly matched 1:1 to cases using simple random sampling. Postal code was selected as a matching factor to help account for differences in disease, immunization, and testing prevalence, and unmeasured social factors. A sample size of 500 matched case and control pairs (n=1000) was estimated to provide >99% statistical power to detect an overall VE >50% with an immunization prevalence of at least 30%, or >80% statistical power to identify a VE >65% for specific vaccine types with a prevalence >5%.

Statistical assessment of differences between cases and controls were performed using the likelihood ratio chi-square test for categorical variables or the two sided Wilcoxon rank-sum test to assess differences between continuous characteristics, with a significance level of $P < 0.05$ in both circumstances.

We assessed vaccination status, matching factors, and potential confounders using bivariate statistics. Conditional multivariate logistic regression analysis was performed to calculate odds ratios (OR) for the association between SARS-CoV-2 infection and receipt of FDA EUA COVID-19 immunizations between cases and controls. VE was estimated as $(1 - \text{OR}) \times 100\%$ [28]. VE estimates were assessed overall and individually for each FDA EUA vaccine. Conditional logistic regression was performed to preserve matching since vaccination status for controls was based on the specimen date of their matched case. Age and postal code were fixed in all models to control for residual or introduced confounding as a result of matching [29, 30].

This was considered public health practice by the MCHD Project Review Team as this assessment consisted only of analysis of routinely-collected reportable disease data. No cases or controls were contacted or interviewed as part of this assessment. All analyses were performed in SAS v 9.4 (SAS Institute Inc., Cary NC 2008).

Results

Case Population Characteristics

From July 1st through July 31st 2021, Multnomah County experienced an epidemic expansion coinciding with increased prevalence of Delta variant (32 of 41 [78%] sequences available at time of writing from July), resulting in 1398 confirmed SARS-CoV-2 infections being reported (Figure 1). Among these, 1156 (93.5%) met the inclusion criteria. During this same time, >30,000 negative lab results were reported for eligible controls. Cases and Controls were matched on age strata (ranked octiles of the case age distribution) and postal code, resulting in 500 matched pairs (500 cases, 500 controls). Immunization prevalence during July among individuals over 15 years of age ranged from 70-71% with increasing immunization prevalence with age (Table S1, [27]).

The majority of cases were confirmed via RT-PCR (92%), median age was 37 years, 55% were female, 60% were white non-hispanic, 12% were of unknown race or ethnicity, 11% were black non-hispanic, 10 % were hispanic of any race, and 3.8% were asian non-hispanic (Table 1). Twenty-four (4.8%) cases were hospitalized as a result of COVID-19 and 1 death occurred. Forty percent of cases were fully immunized (UTD), 4% were previously immunized-NUTD, and 56% were completely unvaccinated.

Case and Control Comparisons

No differences between cases and controls were identified for sex or age. Cases were more likely to be black non-hispanic, compared to controls (Table 2). Cases were more likely than controls to be unvaccinated (55.8% [n=279] vs. 29.0% [n=145]) and were more likely to have immunization records in the ALERT IIS datasystem (96.6% [n=483] vs 94.0% [n=470], $P=0.06$). The median period from completion of COVID-19 immunizations until the matched case's SARS-CoV-2 positive specimen were equivalent between cases and controls (102 days vs. 97 days $P=0.29$, respectively). No differences in this period were identified between cases and controls for specific COVID-19 Vaccines.

Vaccine Effectiveness Assessment

Cases were significantly less likely to have started or completed all COVID-19 immunizations in bivariate analyses. In multivariate analyses, after adjustment for matching factors, we assessed additional potential confounding factors including race and ethnicity and sex. However, none of these factors were significantly different between cases and controls or confounded the point estimates (>10% change). The final model included immunization adjusted for age and postal code only (Table 3). Upon adjustment for matching factors, VE was moderately high at 73% for both UTD and NUTD vaccination statuses (Table 4).

Examination of specific immunizations revealed that both mRNA immunizations (BNT162b2 and mRNA-1273) had similar effect magnitudes and were not significantly different from each other (OR 0.3-0.26 for UTD and 0.29-0.31 for NUTD respectively). In contrast Ad26.COV2.S displayed a lower effect magnitude relative to the mRNA immunizations. Therefore, mRNA immunizations were combined into “mRNA UTD” and “mRNA NUTD” categories with a separate “UTD J&J” category to improve statistical power and investigate immunization specific VE in multivariate models.

After adjustment for matching factors, no other covariates were significantly different between cases and controls or confounded the association with immunization status. Cases were less likely than controls to have been UTD and NUTD for mRNA immunizations (OR 0.26 95% CI 0.15-0.35 $P<0.001$ and 0.28 95% CI 0.15-0.53 $P=0.06$ respectively, Table 3). In contrast, Ad26.COV2.S displayed reduced effect magnitude between cases and controls (OR 0.49 95% CI 0.24-1.02, $P=0.60$). VE for mRNA vaccines was 74% (95% CI 65-82%) for UTD individuals, 72% (95% CI 47-85%) for NUTD individuals, and 51% (95% CI -2-76%) for UTD-Ad26.COV2.S individuals (Table 4).

Exclusion of matched pairs where either a case or control was missing an immunization record (resultant $n=910$, 455 matched pairs), resulted in the same overall models (Table S2). As expected, the magnitude of the VE estimates increased across mRNA immunizations (79% 95% CI 70-86% for UTD and 78% 95% CI 57-89% for NUTD) as well as Ad26.COV2.S 58% (95% CI 12-80%) (Table S3). Sensitivity analyses varying acceptable dose spacing and the interval for protection following series completion (10-28 days), resulted in the same overall models with slight changes in the NUTD estimates only. Finally, utilization of unconditional vs. conditional logistic regression resulted in differences in VE estimation precision but did not change overall VE conclusions (data not shown).

Discussion

To our knowledge, this is the first metropolitan county wide assessment of COVID-19 vaccine effectiveness during an epidemic expansion driven, in part, by the dissemination of Delta variant. We demonstrate instantaneous measures of VE for Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273), and Janssen (Ad26.COV2.S) vaccinations against SARS-CoV-2 infection during July, 2021. We enumerate that individuals >15 years of age with primary SARS-CoV-2 infection had highly reduced odds of receiving any COVID-19 immunizations compared to matched community controls, particularly among individuals that received mRNA immunizations. Our VE estimates indicate moderate to high protection during our local Delta variant driven epidemic expansion.

Our VE estimates for mRNA immunizations align with international and national observational studies that have estimated moderate to reduced VE for Delta variant (65-82% VE for mRNA immunizations, [21-23]). However, our findings do not support the dramatic reductions in VE reported elsewhere [24, 25]. Differences in study populations, vaccination types and vaccine uptake timelines, study design, and viral diversity may explain some of these differences. Despite methodological differences, our overall results align well with a VE assessment in New York State during Delta variant dissemination where vaccination availability and prevalence were similar [23]. Importantly, we were able to assess differences in vaccine performance across all COVID-19 immunizations including partially immunized populations. In

contrast to other reports, we found no significant differences in vaccine performance between mRNA immunizations (BNT162b2, mRNA-1273) during the Delta variant driven epidemic expansion. However, we had insufficient statistical power to generate precise VE estimates for Ad26.COV2.S, though our point estimate indicated moderate VE.

Alarming, our VE estimates here are significantly reduced compared to a methodologically equivalent VE assessment we performed with cases tested a median of 6 weeks prior (June, 2021). During this previous assessment, immunization prevalence was equivalently static, disease prevalence was in decline, and the Delta variant did not represent a meaningful fraction of known COVID-19 cases in Multnomah County (Tables S4-S6). VE findings from our previous assessment aligned with clinical trial and observational study estimates of mRNA immunization performance [12-20]. Therefore, the reduction in VE reported here likely indicates that this change was not attributable to methodological differences with our approach. Interestingly, the interval from full vaccination until the matched case's positive specimen date was equivalent between cases and controls. A longer interval for cases would have been indicative of waning of immunity with time. Collectively, these findings strongly suggest that the rapid reduction in VE within our population is explained by reduced overall vaccine performance against Delta variant [23].

The TND case-control methodology provided a strong instantaneous measure of vaccine performance during our Delta variant epidemic expansion. Our evaluation was semi-automated and interview-independent, facilitating repeatable VE assessments in near real-time. Additional advantages of this approach include being able to directly or indirectly control differences in age, health seeking behavior, case ascertainment, and social and demographic factors reported via ELR or related to postal code [28]. Nevertheless, this approach may limit generalizability to other populations where immunization uptake and Delta variant predominance differ. The immunization prevalence among controls was significantly lower than the locally estimated immunization prevalence during the study period (Table S1, [27]). This discrepancy is explained by non-homogenous vaccine prevalence across our population. Therefore, our case and control matching criteria help to account for immunization heterogeneity resulting in more robust VE estimates.

Exclusion of cases and possible controls that were reported via eCR testing minimized differential biases due to differences in reporting of test results and limited the influence of outbreaks within special populations. Consequently, our VE estimates may not be generalizable to congregate settings including long term care facilities where eCR testing predominates and vaccine performance may differ [31, 32]. Relatedly, we were unable to include additional factors associated with reduced vaccine performance including fragility and immune suppression, because medical record review was not performed [31-35].

The observational nature of this study has limitations. Namely, immunization ascertainment was marginally elevated for cases compared to controls because public health case investigators collect immunization records from cases and enter these data into ALERT IIS. This would differentially inflate immunization prevalence among cases resulting in VE underestimates. Similarly, provider documented, highly specific immunization status criteria reduced the possibility of misclassification. However, classification of cases and controls with missing immunization registry records as unvaccinated would also result in VE underestimates. Indeed, exclusion of matched pairs where either a case or a control was missing immunization status, resulted in significant increases in estimated VE. Surveillance data can result in biased case ascertainment if health seeking and COVID-19 testing differ with respect to disease severity or immunization status. This would tend to result in controls having lower immunization prevalence, biasing towards VE underestimates. Similarly, case ascertainment for prior SARS-CoV-2 infection likely resulted in differences in re-infection risk. This misclassification would tend to

underestimate VE if more unvaccinated controls had protection due to primary infection [36, 37]. Finally, we only assessed VE for infection. Therefore, additional benefits of immunization including reduced COVID-19 severity are not realized with our methodology. Collectively, these small potential biases would serve to underestimate VE making our estimates conservative.

The moderate to high VE during a Delta variant related surge, highlights the overall success of COVID-19 immunizations in contributing to reductions in the SARS-CoV-2 infection rate at the population level. Nonetheless, the high incidence of vaccine breakthrough infections within our population also illuminates the individual susceptibility to infection even among immunized individuals. Unfortunately, the high VE against SARS-CoV-2 infection reported here and elsewhere is likely insufficient to maintain an infection rate below 1 for variants as transmissible as Delta variant without additional non-pharmaceutical interventions (NPI) [38]. Thus, immunizations in concert with additional NPIs for both vaccinated and unvaccinated populations are necessary to limit epidemic oscillations. Future research should evaluate immunization benefits beyond infection including reducing severe outcomes [23, 37]. Studies to date have conflated the prophylactic benefits of immunization with reduced hospitalization and death for the estimation of VE [17, 19]. Whereas, declining prophylactic VE may result in increasing disease severity if the majority of protection is attributable to COVID-19 vaccines preventing infection. Therefore, research is needed to evaluate outcomes among vaccine breakthrough infections. Finally, booster doses have been proposed to improve VE [40]. However, boosting with the same formulation may not result in concomitant increases in VE if changes in protection are principally driven by viral genetic drift. Consequently, rational vaccine reformulations targeting multiple immunogenic components of the viral life cycle may be necessary.

Notes

Disclosures

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf

Acknowledgements

We thank Jennifer Vines and Kim Toevs (Multnomah County Health Department) for providing constructive input. We also thank Oregon ALERT IIS staff (Oregon Health Authority), Acute and Communicable Disease Interoperability Staff (Oregon Health Authority), and Multnomah County Information Technology and Orpheus/Opera “datamart” staff (Multnomah County Health Department) for developing and maintaining data structures utilized for this work.

Financial support

This study/report was supported in part by an appointment to the Applied Epidemiology Fellowship Program administered by the Council of State and Territorial Epidemiologists (CSTE) and funded by the Centers for Disease Control and Prevention (CDC) Cooperative Agreement Number 1NU38OT000297-03-00.

Potential conflicts of interest

All authors: No reported conflicts

References

1. Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). COVID-19 Dashboard. Available at: <https://coronavirus.jhu.edu/map.html>.
2. Hinton D. Pfizer-BioNTech COVID-19 Vaccine EUA Letter of Authorization reissued 05-10-2021. 2021; Available at: <https://www.fda.gov/media/144412/download>. Accessed 19 August 2021.
3. Hinton D. Moderna COVID-19 Vaccine EUA Letter of Authorization. 2021; Available at: <https://www.fda.gov/media/144636/download>. Accessed 19 August 2021.
4. Hinton D. Janssen COVID-19 Vaccine EUA Letter of Authorization 06102021. 2021; Available at: <https://www.fda.gov/media/146303/download>. Accessed 19 August 2021.
5. Oliver SE, Gargano JW, Marin M, et al. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020. MMWR Morb Mortal Wkly Rep 2020; 69:1922–1924.
6. Oliver SE, Gargano JW, Marin M, et al. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020. MMWR Morb Mortal Wkly Rep 2021; 69:1653–1656.
7. Oliver SE, Gargano JW, Scobie H, et al. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021. MMWR Morb Mortal Wkly Rep 2021; 70:329–332.
8. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020; 383:2603–2615
9. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021; 384:403–416
10. Thomas SJ, Moreira ED, Kitchin N, et al. Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. Infectious Diseases (except HIV/AIDS), 2021. medRxiv 2021.07.28.21261159.
11. Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med 2021; 384:2187–2201
12. Angel Y, Spitzer A, Henig O, et al. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers. JAMA 2021; Available at: <https://jamanetwork.com/journals/jama/fullarticle/2779853>. Accessed 21 May 2021.
13. Pilishvili T, Fleming-Dutra KE, Farrar JL, et al. Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel - 33 U.S. Sites, January–March 2021. MMWR Morb Mortal Wkly Rep 2021;70:753–758.
14. Yelin I, Katz R, Herzel E, et al. Associations of the BNT162b2 COVID-19 vaccine effectiveness with patient age and comorbidities. Infectious Diseases (except HIV/AIDS), 2021. medRxiv 2021.03.16.21253686.
15. Tang L, Hijano DR, Gaur AH, et al. Asymptomatic and Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a Routinely Screened Workforce. JAMA 2021; Available at: <https://jamanetwork.com/journals/jama/fullarticle/2779854>. Accessed 21 May 2021.
16. Swift MD, Breeher LE, Tande AJ, et al. Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel. Clin Infect Dis 2021; :ciab361.
17. Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. The Lancet 2021; 397:1819–1829.

18. Thompson MG, Burgess JL, Naleway AL, et al. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021. *MMWR Morb Mortal Wkly Rep* 2021; 70:495–500.
19. Vasileiou E, Simpson CR, Shi T, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. *The Lancet* 2021; 397:1646–1657.
20. Kissling E, Hooiveld M, Sandonis Martín V, et al. Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021. *Euro Surveill.* 2021 Jul;26(29):2100670.
21. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *N Engl J Med* 2021; 385:585–594.
22. Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. *The Lancet* 2021; 397:2461–2462.
23. Rosenberg ES, Holtgrave DR, Dorabawila V, et al. New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status - New York, May 3–July 25, 2021. *MMWR Morb Mortal Wkly Rep.* ePub: 18 August 2021.
24. Puranki A, Lenehan P, Silvert E, et al. Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. *medRxiv* 2021.08.06.21261707
25. Israel Ministry of Health. Data Compiled by the Vaccine Operations Supervising Committee Published. <https://www.gov.il/en/departments/news/22072021-03> Accessed 17 August 2021.
26. Portland State University Population Research Center Available at: <https://www.pdx.edu/population-research/population-estimate-reports>. Accessed 17 August 2021
27. Oregon Health Authority COVID-19: Oregon COVID-19 Vaccine Effort Metrics. Available at: <https://rb.gy/c1enf5>. Accessed: 17 August 2021.
28. De Serres G, Skowronski DM, Wu XW, Ambrose CS. The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials. *Euro Surveill.* 2013 Sep 12;18(37):20585.
29. Mansournia MA, Hernán MA, Greenland S. Matched designs and causal diagrams, *Int J of Epidemiol* 2013;18:860–869
30. Pearce N. Analysis of matched case-control studies. *BMJ* 2016; :i969.
31. Emborg HD, Valentiner-Branth P, Schelde AB, et al. Vaccine effectiveness of the BNT162b2 mRNA COVID-19 vaccine against RT-PCR confirmed SARS-CoV-2 infections, hospitalisations and mortality in prioritised risk groups. *medRxiv* 2021.05.27.21257583
32. Monge S, Olmedo C, Alejos B, et al. COVID-19 Registries Study Group2. Direct and Indirect Effectiveness of mRNA Vaccination against Severe Acute Respiratory Syndrome Coronavirus 2 in Long-Term Care Facilities, Spain. *Emerg Infect Dis.* 2021 Jul 27;27(10).
33. Butt AA, Khan T, Yan P, Shaikh OS, Omer SB, Mayr F. Rate and risk factors for breakthrough SARS-CoV-2 infection after vaccination. *J Infect.* 2021 Aug;83(2):237–279.
34. Ravanan R, Mumford L, Ushiro-Lumb I, Callaghan C, Pettigrew G, Thorburn D, Gardiner D, Forsythe J; OTDT Clinical Team. Two Doses of SARS-CoV-2 Vaccines Reduce Risk of Death Due to COVID-19 in Solid Organ Transplant Recipients: Preliminary Outcomes From a UK Registry Linkage Analysis. *Transplantation.* 2021 Jul 23.
35. Antoneli M, Penfold RS, Merino J, et al. Post-vaccination SARS-CoV-2 infection: risk factors and illness profile in a prospective, observational community-based case-control study. *medRxiv* 2021.05.24.21257738

36. Vitale J, Mumoli N, Clerici P, et al. Assessment of SARS-CoV-2 Reinfection 1 Year After Primary Infection in a Population in Lombardy, Italy. *JAMA Intern Med.* 2021 May
37. Breathnach AS, Duncan CJA, Bouzidi KE, et al. Prior COVID-19 protects against reinfection, even in the absence of detectable antibodies. *J Infect.* 2021 Aug;83(2):237-279.
38. Liu Y, Rocklöv J. The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus. *J Travel Med.* 2021 Aug 9:taab124. doi: 10.1093/jtm/taab124.
39. Tenforde MW, Patel MM, Ginde AA, et al. Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States. *Clin Infect Dis* 2021; :ciab687.
40. The White House. Press Briefing by White House COVID-19 Response Team and Public Health Officials. <https://rb.gy/rqeboh>. Accessed 19 August 2021

Figures and Tables

Figure 1. Case-Control Eligibility and Selection Flow chart, Multnomah County Oregon, July 2021

Table 1: SARS-CoV-2 Case Demographic and Clinical Characteristics. Multnomah County Oregon, July 2021 (n=500)

Demographic Characteristics	No. Patients	%
Sex		
Female	264	52.8
Male	236	47.2
Age group		
16–19	20	4.0
20s	139	27.8
30s	123	24.6
40s	78	15.6
50s	66	13.2
60s	40	8.0
70s	25	5.0
80+	9	1.8
Race		
Alaska Indian/American Native, non-Hispanic	4	0.8
Asian, non-Hispanic	19	3.8
Black, non-Hispanic	57	11.4
Hispanic, any race	52	10.4
Multiracial/Other	24	4.8
Pacific Islander, non-Hispanic	3	0.6
Unknown/Refused	60	12.0
White	281	56.2
Clinical Characteristics	No. Patients	%
Laboratory Test Type		
PCR	460	92.0
Antigen	40	8.0
Severe Illness Outcomes		
Hospitalized	24	4.8
Death	1	0.3
Vaccination Status		
Un-vaccinated	279	55.8
Previously vaccinated, not up-to-date (NUTD)	19	3.8
Up-to-date (UTD)	202	40.4
Vaccine Types		
UTD-BNT162b2	141	28.2
UTD-mRNA-1273	39	7.8
UTD-Ad26.COV2.S	22	4.4
NUTD-BNT162b2	13	2.6
NUTD-mRNA-1273	6	1.2

Abbreviations: PCR, polymerase chain reaction

Table 2: COVID-19 Case and Control Demographics and Immunization Comparisons. Multnomah County Oregon, July 2021 (n=1000)

Characteristics	No. Patients	%	No. Controls	%	P Value
Sex					
Female	264	52.8	273	54.6	Referent
Male	236	47.2	227	45.4	0.56
Race					
Alaska Indian/American Native, non-Hispanic	4	0.8	3	0.6	0.72
Asian, non-Hispanic	19	3.8	28	5.6	0.15
Black, non-Hispanic	57	11.4	27	5.4	0.01
Hispanic, any race	52	10.4	30	6.0	0.08
Multiracial/Other	24	4.8	23	4.6	0.93
Pacific Islander, non-Hispanic	3	0.6	7	1.4	0.13
Unknown/Refused	60	12.0	67	13.4	0.4
White	281	56.2	315	63.0	Referent
Vaccine Registry					
Able to locate individual	483	96.6	470	94.0	Referent
Unable to locate individual	17	3.4	30	6.0	0.06
Coincident Immunizations (<14 days before test date)	3	0.6	1	0.2	--
Vaccination Status					
Un-vaccinated	279	55.8	145	29.0	Referent
Previously vaccinated, not up-to-date (NUTD)	19	3.8	32	6.4	0.05
Up-to-date (UTD)	202	40.4	323	64.6	<0.001
Vaccine Types					
UTD-BNT162b2	141	28.2	231	46.2	<0.001
UTD-mRNA-1273	39	7.8	74	14.8	0.01
UTD-Ad26.COVS2.S	22	4.4	18	3.6	0.06
NUTD-BNT162b2	13	2.6	20	4.0	0.61
NUTD-mRNA-1273	6	1.2	12	2.4	0.44
Continuous Characteristics	Median: Patients	IQR	Median: Controls	IQR	P Value
Age (years)	37	28-52	37	28-52	0.98
Vaccine Interval (last dose to case test date, days)					
UTD-Any Vaccine	102	74-136	97	73-139	0.29
UTD-BNT162b2	102	75-134	93	75-133	0.23
UTD-mRNA-1273	113	73-156	109.5	69-152	0.71
UTD-Ad26.COVS2.S	99	65-120	99	57-115	0.51

Abbreviations: IQR, interquartile range

*Likelihood ratio chi-square test

^two-sided Wilcoxon rank sum test

Values in bold indicate statistical significance, $P < 0.05$

Table 3: Case and Control Vaccination Status Associations With Odds of SARS-CoV-2 Infection. Multnomah County Oregon, July 2021 (n=1000)

Characteristics	No. Patients	%	No. Controls	%	OR (95%CI)	Adjusted OR (95% CI)*	P Value
Vaccination Status							
Un-vaccinated	279	55.8	145	29.0		Referent	
Previously vaccinated, not up-to-date (NUTD)	19	3.8	32	6.4	0.29 (0.16-0.54)	0.27 (0.14-0.51)	0.03
Up-to-date (UTD)	202	40.4	323	64.6	0.31 (0.23-0.41)	0.27 (0.19-0.37)	<0.001
Vaccine Types							
UTD-BNT162b2	141	28.2	231	46.2	0.30 (0.22-0.42)	--	--
UTD-mRNA-1273	39	7.8	74	14.8	0.26 (0.17-0.42)	--	--
UTD-Ad26.COV2.S	22	4.4	18	3.6	0.57 (0.29-1.16)	--	--
NUTD-BNT162b2	13	2.6	20	4.0	0.29 (0.14-0.63)	--	--
NUTD-mRNA-1273	6	1.2	12	2.4	0.31 (0.11-0.86)	--	--
Aggregated Vaccination Status							
NUTD-mRNA	19	3.8	32	6.4	0.30 (0.16-0.55)	0.28 (0.15-0.53)	0.07
UTD-mRNA	180	36.0	305	61.0	0.29 (0.22-0.40)	0.26 (0.18-0.35)	<0.001
UTD-Ad26.COV2.S	22	4.4	18	3.6	0.57 (0.29-1.15)	0.49 (0.24-1.02)	0.63

Abbreviations: CI, confidence interval; OR, Odds Ratio; mRNA, either mRNA immunization (BNT162b2 or mRNA-1273)

*matched and statistically adjusted by postal code and age

Values in bold indicate statistical significance, $P < 0.05$

Table 4: COVID-19 Vaccine Effectiveness Estimates. Multnomah County Oregon, July 2021 (n=1000)

Study Characteristics	Vaccine Effectiveness		
	Estimate (%)*	95% LL	95% UL
Vaccination Status			
Un-vaccinated		Referent	
Previously vaccinated, not up-to-date (NUTD)	73	49	86
Up-to-date (UTD)	73	63	81
Aggregated Vaccination Status			
NUTD-mRNA	72	47	85
UTD-mRNA	74	65	82
UTD-Ad26.COVS.S	51	-2	76

Abbreviations: CI, confidence interval; LL, lower limit; UL, upper limit; mRNA, either mRNA immunization (BNT162b2 or mRNA-1273)

*matched and statistically adjusted by postal code and age

Values in bold indicate statistical significance, $P < 0.05$

Supplementary Figures and Tables

Table S1: Population Immunization Prevalence Characteristics During Case-Control Vaccine Effectiveness Assessment, Multnomah County Oregon, July 2021

	Vaccine Effectiveness			
	Assessment period	Median	Min	Max
Case-control				
Characteristics	Specimen Date	7/24/2021	7/1/2021	07/31/2021
Multnomah County >15 year old population COVID-19 immunization characteristics*	Median Age Among Immunized (years)	45	47	45
	Un-vaccinated	25%	27%	25%
	Previously vaccinated, not up-to-date (NUTD)	4%	3%	4%
	Up-to-date (UTD)	71%	70%	71%

**Unofficial data courtesy of Oregon ALERT Immunization Information System (ALERT IIS) jurisdictional access data extracts. Similar public data are available at: [27]*

Table S2: Case and Control Vaccination Status Associations With Odds of SARS-CoV-2 Infection, Excluding Case-Control Pairs With Missing Immunization Status. Multnomah County Oregon, July 2021 (n=910)

Study Characteristics	No. Patients	%	No Controls	%	OR (95%CI)	Adjusted OR (95% CI)*	P Value
Vaccination Status							
Un-vaccinated	247	54.3	112	24.6		Referent	
Previously vaccinated, not up-to-date (NUTD)	17	3.7	30	6.6	0.23 (0.12-0.44)	0.21 (0.10-0.41)	0.01
Up-to-date (UTD)	191	42.0	313	68.8	0.26 (0.19-0.36)	0.22 (0.15-0.31)	<0.001
Vaccine Types							
NUTD-mRNA	17	3.7	30	6.6	0.24 (0.17-0.34)	0.22 (0.11-0.43)	0.04
UTD-mRNA	169	37.1	295	64.8	0.24 (0.17-0.34)	0.21 (0.14-0.30)	<0.001
UTD-Ad26.COV2.S	22	4.8	18	4.0	0.51 (0.25-1.03)	0.42 (0.20-0.88)	0.67

Abbreviations: CI, confidence interval; OR, Odds Ratio; mRNA, either mRNA immunization (BNT162b2 or mRNA-1273)

*matched and statistically adjusted by postal code and age

Values in bold indicate statistical significance, $P < 0.05$

Table S3: COVID-19 Vaccine Effectiveness Estimates, Excluding Case-Control Pairs With Missing Immunization Status. Multnomah County Oregon, July 2021 (n=910)

Study Characteristics	Vaccine Effectiveness		
	Estimate (%)*	95% CI LL	95% CI UL
Vaccination Status			
Un-vaccinated		Referent	
Previously vaccinated, not up-to-date (NUTD)	79	59	90
Up-to-date (UTD)	78	69	85
Aggregated Vaccination Status			
Un-vaccinated		Referent	
NUTD-mRNA	78	57	89
UTD-mRNA	79	70	86
UTD-Ad26.COV2.S	58	12	80

Abbreviations: CI, confidence interval; LL, lower limit; UL, upper limit; mRNA, either mRNA immunization (BNT162b2 or mRNA-1273)

*matched and statistically adjusted by postal code and age

Values in bold indicate statistical significance, $P < 0.05$

Table S4: COVID-19 Case and Control Demographics and Immunization Comparisons. Multnomah County Oregon, June 2021 (n=600)

Study Characteristics	No. Patients	%	No. Controls	%	P Value*
Sex					
Female	166	53.3	187	62.3	Referent
Male	134	44.7	113	37.7	0.08
Race					
Alaska Indian/American Native, non-Hispanic	5	1.7	2	0.7	0.11
Asian, non-Hispanic	6	2.0	15	5.0	0.03
Black, non-Hispanic	42	14.1	24	8.0	0.04
Hispanic, any race	39	13.1	21	7.0	0.05
Multiracial/Other	9	3.0	22	7.3	0.03
Pacific Islander, non-Hispanic	2	0.7	4	1.3	0.31
Unknown/Refused	42	14.0	30	10.0	0.15
White	155	52.2	182	60.7	Referent
Vaccine Registry					
Able to locate individual	279	93.0	286	95.3	Referent
Unable to locate individual	21	7.0	14	4.7	0.22
Coincident Immunizations (<14 days before test date)	7	2.3	8	2.7	1.00
Vaccination Status					
Un-vaccinated	235	78.3	110	36.7	Referent
Previously vaccinated, not up-to-date (NUTD)	10	3.3	25	8.3	0.05
Up-to-date (UTD)	55	18.3	165	55.0	<0.001
Vaccine Types					
UTD-BNT162b2	32	10.7	111	37.0	<0.001
UTD- mRNA-1273	13	4.33	50	16.7	0.01
UTD-Ad26.COV2.S	10	3.33	4	1.3	0.06
NUTD-BNT162b2	8	2.7	15	5.0	0.61
NUTD- mRNA-1273	2	0.67	10	3.3	0.44
Continuous Characteristics	Median: Patients	IQR	Median: Controls	IQR	P Value^
Age (Years)	40	29-54	39.5	29-56	0.64
Vaccine Interval (last dose to case test date, days)					
UTD-BNT162b2	97.5	49.5-113.5	63	41-108	0.13
UTD- mRNA-1273	88	58-144	83	33-121	0.07
UTD-Ad26.COV2.S	80.5	68-93	82	77-92	0.62

Abbreviations: IQR, interquartile range

*Likelihood ratio chi-square test

^two-sided Wilcoxon rank sum test

Values in bold indicate statistical significance, P<0.05

Table S5: Case and Control Vaccination Status Associations With Odds of SARS-CoV-2 Infection. Multnomah County Oregon, June 2021 (n=600)

Study Characteristics	No. Patients	%	No Controls	%	OR (95%CI)	Adjusted OR (95% CI)*
Vaccination Status						
Un-vaccinated	237	78.3	110	36.7		Referent
Previously vaccinated, not up-to-date (NUTD)	10	3.3	25	8.3	0.18 (0.08-0.43)	0.17 (0.07-0.41)
Up-to-date (UTD)	55	18.3	165	55.0	0.15 (0.09-0.23)	0.13 (0.08-0.22)
Vaccine Types						
UTD-BNT162b2	32	10.7	111	37.0	0.14 (0.09-0.22)	0.11 (0.06-0.19)
UTD-mRNA-1273	13	4.33	50	16.7	0.12 (0.06-0.24)	0.10 (0.05-0.23)
UTD-Ad26.COV2.S	10	3.33	4	1.3	1.18 (0.36-3.85)	1.18 (0.31-4.5)
NUTD-BNT162b2	8	2.7	15	5.0	0.25 (0.02-0.44)	0.23 (0.08-0.69)
NUTD-mRNA-1273	2	0.67	10	3.3	0.09 (0.02-0.44)	0.07 (0.01-0.41)
Aggregated Vaccine Types						
NUTD-mRNA	10	3.3	25	8.3	0.18 (0.07-0.43)	0.16 (0.06-0.40)
UTD-mRNA	45	15.0	161	78.2	0.12 (0.07-0.20)	0.11 (0.06-0.18)
UTD-Ad26.COV2.S	10	3.3	4	1.3	1.13 (0.32-4.04)	1.26 (0.33-4.88)

Abbreviations: CI, confidence interval; OR, Odds Ratio; mRNA, either mRNA immunization (BNT162b2 or mRNA-1273)

*matched on zipcode and age and statistically adjusted by sex and age

Values in bold indicate statistical significance, $P < 0.05$

Table S6: COVID-19 Vaccine Effectiveness Estimates. Multnomah County Oregon, June 2021 (n=600)

Study Characteristics	Vaccine Effectiveness		
	Estimate (%)*	95% LL	95% UL
Vaccination Status			
Un-vaccinated		Referent	
Previously vaccinated, not up-to-date (NUTD)	83	59	93
Up-to-date (UTD)	87	78	92
Aggregated Vaccination Status			
NUTD-mRNA	84	60	94
UTD-mRNA	89	82	94
UTD-Ad26.COV2.S	-26	-488	67

Abbreviations: CI, confidence interval; LL, lower limit; UL, upper limit; mRNA, either mRNA immunization (BNT162b2 or mRNA-1273)

*matched on zipcode and age and statistically adjusted by sex and age

Values in bold indicate statistical significance, $P < 0.05$